Shang Hai Zheng Quan Bao·2025-12-16 19:16Group 1 - The company has decided to waive its preferential purchase rights for a 4.04% stake in Zhongpu Biopharmaceutical Co., Ltd., held by CITIC Agricultural Technology Co., Ltd., allowing the stake to be acquired by Plaikou Biological Engineering Co., Ltd. or other third parties [1] - The transaction was approved during the company's board meeting on November 13, 2025, and the third extraordinary general meeting of shareholders on December 1, 2025 [1] - This transaction does not constitute a related party transaction or a major asset restructuring [1] Group 2 - On December 15, 2025, the company received a certificate confirming that Plaikou is the buyer of the stake, with the transaction price set at 17.5143 million yuan, to be paid in a lump sum [2] - After the completion of the share transfer, the company will retain a 48.99% stake in Zhongpu Biopharmaceutical, which will no longer be a subsidiary, and its financial data will not be included in the company's consolidated financial statements [2] - The company asserts that these changes will not harm the interests of the company and its shareholders, with the final impact on the 2025 financial data to be determined in the annual report [2]